Innovative γ-Oryzanol and KC2 Based Lipid Nanoparticles: OryKL Platform Provides Safe and Efficient In Vivo mRNA Delivery.

Saved in:
Bibliographic Details
Title: Innovative γ-Oryzanol and KC2 Based Lipid Nanoparticles: OryKL Platform Provides Safe and Efficient In Vivo mRNA Delivery.
Authors: Shi P; Centre For Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Molecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Baker Department of Cardiometabolic Health, University of Melbourne, Parkville, Victoria, Australia., Liu H; Centre For Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Molecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Baker Department of Cardiometabolic Health, University of Melbourne, Parkville, Victoria, Australia., Refaat A; Centre For Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Molecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Baker Department of Cardiometabolic Health, University of Melbourne, Parkville, Victoria, Australia.; Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Nguyen H; Centre For Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Molecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Baker Department of Cardiometabolic Health, University of Melbourne, Parkville, Victoria, Australia., Nguyen A; Centre For Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Molecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Miao K; Centre For Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Molecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; School of Translational Medicine, Monash University, Melbourne, Victoria, Australia., Song Y; Centre For Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Molecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Baker Department of Cardiometabolic Health, University of Melbourne, Parkville, Victoria, Australia., Trépout S; Ramaciotti Centre for Cryo-Electron Microscopy, Monash University, Clayton, Victoria, Australia., Tabor RF; School of Chemistry, Monash University, Clayton, Victoria, Australia.; BioPRIA, Department of Chemical Engineering, Monash University, Clayton, Victoria, Australia., de Campo L; Australian Nuclear Science and Technology Organisation (ANSTO), Lucas Heights, New South Wales, Australia., Peter K; Centre For Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Baker Department of Cardiometabolic Health, University of Melbourne, Parkville, Victoria, Australia.; Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.; Baker Department of Cardiovascular Research, Translation and Implementation, La Trobe University, Bundoora, Victoria, Australia., Vidallon MLP; Centre For Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Molecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Baker Department of Cardiometabolic Health, University of Melbourne, Parkville, Victoria, Australia.; School of Chemistry, Monash University, Clayton, Victoria, Australia.; Baker Department of Cardiovascular Research, Translation and Implementation, La Trobe University, Bundoora, Victoria, Australia., Wang X; Centre For Cardiometabolic mRNA Therapy, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Molecular Imaging and NanoTherapeutics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Baker Department of Cardiometabolic Health, University of Melbourne, Parkville, Victoria, Australia.; School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.; Baker Department of Cardiovascular Research, Translation and Implementation, La Trobe University, Bundoora, Victoria, Australia.
Source: Small (Weinheim an der Bergstrasse, Germany) [Small] 2026 May; Vol. 22 (26), pp. e11946. Date of Electronic Publication: 2026 Mar 18.
Publication Type: Journal Article
Journal Info: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 101235338 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1613-6829 (Electronic) Linking ISSN: 16136810 NLM ISO Abbreviation: Small Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1613-6829
DOI:10.1002/smll.202511946